The association of HIV and other risk factors with triple-negative breast cancer in South African women.

Authors

null

Jacob Dubner

Columbia University Medical Center, New York, NY

Jacob Dubner , Alfred I. Neugut , Maureen Joffe , Daniel O'Neil , Oluwatosin Ayeni , Wenlong Carl Chen , Ines Buccimazza , Sharon Čačala , Laura Stopforth , Hayley Farrow , Sarah Nietz , Boitumelo Phakathi , Judith Jacobson , Katherine D. Crew , Paul Ruff , Herbert Cubasch , Yoanna S Pumpalova

Organizations

Columbia University Medical Center, New York, NY, Columbia College of Physicians and Surgeons, New York, NY, University of Witwatersrand Faculty of Health Sciences, Johannesburg, South Africa, Yale Cancer Center, Yale School of Medicine, New Haven, CT, University of KwaZulu-Natal, Berea, Durban, South Africa, University of KwaZulu-Natal, Pietermaritzburg, South Africa, University of the Witwatersrand, Johannesburg, South Africa, University Witwatersrand Faculty Health Sciences, Johannesburg, South Africa, Columbia University, New York, NY, University Witwatersrand Faculty Health Sciences, City of Johannesburg, South Africa, Wits, Johannesburg, South Africa

Research Funding

U.S. National Institutes of Health
U.S. National Institutes of Health, Conquer Cancer Foundation of the American Society of Clinical Oncology

Background: Breast cancer (BC) mortality in South Africa (SA) is double that of the United States. The aggressive triple-negative breast cancer (TNBC) subtype comprises 20.9% of BC cases among Black women in Southern Africa. SA has the second highest HIV prevalence worldwide, but if and how HIV affects the risk of developing TNBC is not well understood. Methods: Using the South African Breast Cancer and HIV Outcomes (SABCHO) prospective cohort of newly diagnosed BC patients from six public hospitals in SA, we evaluated the association of HIV with risk of TNBC relative to other BC subtypes. We developed multivariable logistic regression models to test for this association while adjusting for key demographic and reproductive risk factors. Results: Of 3,883 women with BC, 16.4% had TNBC and 23.0% were HIV-positive. The overall median age of BC diagnosis was 55 years. Among HIV positive patients, the median age of BC diagnosis was 45 years, without a difference between TNBC and non-TNBC cases (p = 0.244). Only 7.2% of women were nulliparous (4.6% in TNBC and 7.6% in non-TNBC subgroups). Of women who had at least 1 full-term pregnancy, 11.2% did not breastfeed, without a difference between TNBC and non-TNBC cases (p = 0.292). In our final multivariable logistic regression model, HIV-positive status was associated with increased risk of TNBC relative to non-TNBC (OR: 1.40; 95% CI: 1.12-1.74, compared to HIV-negative with BC). Parity without breastfeeding was also associated with increased risk of TNBC relative to non-TNBC (OR: 1.72; 95% CI: 1.07-2.84, compared to nulliparous with BC). HIV status and the combined parity/breastfeeding variable had no statistically significant interaction. In exploratory analyses, measures of HIV control at time of BC diagnosis were not associated with BC subtype. Conclusions: In this large prospective case-only study conducted in SA, we found that women living with HIV were more likely than HIV-negative women to have TNBC (relative to other BC subtypes), regardless of the extent of HIV control. Whether this relationship is mediated by immune mechanisms or other factors should be the focus of future research. Our findings highlight the importance of rigorous BC screening and early detection among HIV-positive women given their increased relative risk of developing TNBC.

Multivariable logistic regression model for SABCHO cohort adjusting for demographic and reproductive factors (TNBC vs non-TNBC).

FactorExposed CategoryMultivariable Model¡
Odds Ratios (95% CIs)
EthnicityBlack1.21 (0.93-1.60)
Wealth Index0.99 (0.93-1.07)
HIV StatusPositive1.40 (1.12-1.74)
Age of Menarche≥15 years1.06 (0.88-1.29)
Parity and BreastfeedingParous, no breastfeeding1.72 (1.07-2.84)
Parous, breastfeeding1.51 (1.00-2.35)
Ever on ContraceptiveYes1.14 (0.92-1.41)

*Bolded odds ratio indicates p-value < 0.05; ¡Model adjusted for age.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Real-World Data/Outcomes

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6583)

DOI

10.1200/JCO.2023.41.16_suppl.6583

Abstract #

6583

Poster Bd #

75

Abstract Disclosures